E-mail: Anna.Jonasova@vfn.cz
Odborné práce publikované na Linkos.cz
Přehled odborných textů publikovaných autorem na portálu Linkos.cz. Jsou zde uvedeny knihy a brožury, články v Klinické onkologii, tuzemská abstrakta z databáze abstrakt a další texty. Rejstřík není v žádném případě úplným autorským rejstříkem, protože jsou zde uvedeny pouze texty zveřejněné na portálu Linkos.cz.
Publikovaná abstrakta
- 5-Azacytidine and G-CSF Derepressed Chromatin Structure of PU.1 and Its Targets Cebpa and Cbfb In Myelodysplastic Syndrome (MDS)
- Activation of Chromatin Structure Upstream PU.1 Gene and in Vitro Differentiation in High Risk Myelodysplastic Syndrome Following 5-Azacytidine
- Altered Expression of the Repair Genes in CD34+ Cells May be Responsible for Formation and Accumulation of Mutations in MDS Patients
- ATYPICAL DELETED SEGMENTS IN THREE PATIENTS WITH MYELOID MALIGNANCIES AND DELETION 5Q
- Clonal Heterogeneity in Patients with Myelodysplastic Syndromes (MDS) and Complex Karyotypes
- Comparison of DNA Methylation and Expression Status Prior Azacytidine Treatment and their Relationship to Overall Survival and Clinical Response of MDS Patients
- CYTOPENIA PARTICULARLY THROMBOCYTOPENIA AT DIAGNOSIS AS AN IMPORTANT NEGATIVE PROGNOSTIC MARKER FOR PATIENTS WITH ISOLATED 5Q- ABNORMALITY AND NO BLASTS IN BONE MARROW
- DEFERASIROX REPRESENTS AN EFFECTIVE ORAL IRON CHELATOR IN LOW OR INTERMEDIATE-1 RISK PATIENTS WITH MDS – A COMPARATIVE STUDY TO THE TREATMENT WITH DEFERIPRONE
- DNA METHYLATION PROFILING IN PATIENTS WITH MYELODYSPLASTIC SYNDROME TREATED WITH 5-AZACYTIDINE
- EFFECT OF LENALIDOMIDE TREATMENT ON THE EXPRESSION OF FLI1, EKLF, TP53, HDM2, PU. 1 AND IL-6 GENES IN 5Q- SYNDROME
- Efficacy and Safety of Lenalidomide (LEN) Versus Placebo (PBO) in RBC-Transfusion Dependent (TD) Patients (Pts) with IPSS Low/Intermediate (Int-1)-Risk Myelodysplastic Syndromes (MDS) without Del(5q) and Unresponsive or Refractory to Erythropoiesis-Stimulating Agents (ESAs): Results from a Randomized Phase 3 Study (CC-5013-MDS-005)
- EFFICIENCY AND SAFETY OF ADMINISTRATION OF ORAL IRON CHELATOR DEFERIPRONE IN PATIENTS WITH EARLY MYELODYSPLASTIC SYNDROME (MDS)
- Erythroid Transcription Factor GATA-1 Binds and Represses PU.1 Gene – Candidate Mechanism Of Epigenetic Repression Of PU.1 and Inefficient Erythropoiesis In MDS
- Fli-1 and EKLF Gene Expression in Patients with MDS 5q- Syndrome
- Fludarabine, Cyclophosphamide and Rituximab (FCR) Related Prolonged Cytopenia Is Frequent and Adverse Factor Affecting Survival of Patients with Chronic Lymphocytic Leukemia (CLL)
- Gene Expression Changes In Patients with 5q- Syndrome Treated with Lenalidomide
- High Cereblon Expression In Lower Risk Myelodysplastic Syndromes With 5q Deletion Is Associated With The Efficacy Of Lenalidomide
- HIGH LEVELS OF CEREBLON MESSENGER RNA ARE THE CHARACTERISTIC FEATURE OF LOWER RISK MYELODYSPLASTIC SYNDROMES WITH 5Q DELETION AND ARE CONNECTED WITH THE EFFICACY OF LENALIDOMIDE
- Changes of Pro-Inflammatory Cytokines in Bone Marrow of MDS Patients in Response to Treatment with 5-Azacytidine
- CHROMOTHRIPSIS IN BONE MARROW CELLS OF ADULT PATIENTS WITH NEWLY DIAGNOSED MYELODYSPLASTIC SYNDROMES (MDS) WITH COMPLEX KARYOTYPES
- IMMUNOLOGICAL BACKGROUND OF MDS, AN IMPACT ON PROGNOSIS AND PATHOGENESIS OF MDS
- Lenalidomid (Revlimid) v léčbě mnohočetného myelomu – naše první zkušenosti
- Patient-Reported Fatigue, Functional Aspects and Quality of Life in Elderly Patients with High-Risk Myelodysplastic Syndromes. Evidence From a Large Prospective International Study
- PROFILING PATIENTS WITH HIGH-RISK MYELODYSPLASTIC SYNDROMES WHO PREFER TO RECEIVE SURVIVAL PROGNOSTIC INFORMATION. FINAL RESULTS FROM A LARGE INTERNATIONAL PROSPECTIVE COHORT OBSERVATIONAL STUDY
- PŘETÍŽENÍ ŽELEZEM PŘI OPAKOVANÝCH KREVNÍCH PŘEVODECH A MOŽNOSTI JEHO ŘEŠENÍ
- Putative Monosomy 5 In Myelodysplastic Syndromes (MDS) Is Probably Resulting From Chromothripsis
- Safety of Lenalidomide (LEN) 10mg in Non-Del(5q) Versus Del(5q) in the Treatment of Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (MDS): Pooled Analysis of Treatment-Emergent Adverse Events (TEAEs)
- The Prognostic Significance of TP53
- THE ROLE OF TP53 MUTATIONS IN LOW-RISK MDS PATIENTS
- The Significance of Megakaryocytic Transcription Factor Fli1 and Erythroid Transcription Factor EKLF in the Ribosomopathies: 5q Minus Syndrome and Diamond-Blackfan Anemia. the Role of Fli1 in p53 Regulation and in 5q Minus Syndrome Megakaryopoiesis
- THE SIGNIFICANT ASSOCIATION BETWEEN PRIMARY MYELODYSPLASTIC SYNDROME AND SINGLE NUCLEOTIDE POLYMORPHISMS
- Tracking the Somatic Mutations in Azacitidine-Treated MDS Patients Documents Clonal Development and AZA Responsiveness
- Transcription Factor CTCF Inhibits Effects of 5-Azacitidine in MDS/AML Cells
- TRUE MONOSOMY OF CHROMOSOME 5 IS PRESUMABLY NOT AN ISOLATED CYTOGENETIC ENTITY IN MDS
- Vyšetřování buněk účastnících se v buňkami zprostředkované imunologické reakci u MDS. Možný význam nálezů pro patogenezu MDS.
